keyword
https://read.qxmd.com/read/38576231/disruption-of-post-thymic-tolerance-in-skin-reactive-tcr-transgenic-mice-through-the-interaction-of-lymphopenia-and-intestinal-microbiota
#21
JOURNAL ARTICLE
Hodaka Hayabuchi, Yukiko Tokifuji, Hayato Takahashi, Masayuki Amagai, Akihiko Yoshimura, Shunsuke Chikuma
Autoimmune diseases often arise from conditions where the immune system is compromised. While lymphopenia-induced proliferation (LIP) is crucial for immune system development and maturation, it is also caused by environmental insult, such as infection and becomes a risk factor for autoimmunity in adults. We used Dsg3H1 TCR Transgenic mice, whose T cells are designed to recognize desmogrein-3, a skin antigen, to explore the impact of lymphopenia on post-thymic tolerance. Dsg3H1 mice are known to delete the most highly autoreactive T cells in thymus, and develop only subtle immune-mediated pathology in a steady state...
April 5, 2024: International Immunology
https://read.qxmd.com/read/38572008/early-predictors-of-intensive-care-unit-admission-among-covid-19-patients-in-qatar
#22
JOURNAL ARTICLE
Safae Abuyousef, Shaikha Alnaimi, Nabil E Omar, Reem Elajez, Eman Elmekaty, Eiman Abdelfattah-Arafa, Raja Barazi, Rola Ghasoub, Ala Rahhal, Fatima Hamou, Maha Al-Amri, Ahmed Karawia, Fatima Ajaj, Raja Alkhawaja, Ahmed Kardousha, Ahmed Awaisu, Adel Abou-Ali, Mohamad Khatib, Mohammed Aboukamar, Moza Al-Hail
BACKGROUND: COVID-19 is associated with significant morbidity and mortality. This study aimed to explore the early predictors of intensive care unit (ICU) admission among patients with COVID-19. METHODS: This was a case-control study of adult patients with confirmed COVID-19. Cases were defined as patients admitted to ICU during the period February 29-May 29, 2020. For each case enrolled, one control was matched by age and gender. RESULTS: A total of 1,560 patients with confirmed COVID-19 were included...
2024: Frontiers in Public Health
https://read.qxmd.com/read/38561497/low-dose-dengue-virus-3-human-challenge-model-a-phase-1-open-label-study
#23
JOURNAL ARTICLE
Adam T Waickman, Krista Newell, Joseph Q Lu, HengSheng Fang, Mitchell Waldran, Chad Gebo, Jeffrey R Currier, Heather Friberg, Richard G Jarman, Michelle D Klick, Lisa A Ware, Timothy P Endy, Stephen J Thomas
Dengue human infection models present an opportunity to explore the potential of a vaccine, anti-viral or immuno-compound for clinical benefit in a controlled setting. Here we report the outcome of a phase 1 open-label assessment of a low-dose dengue virus 3 (DENV-3) challenge model (NCT04298138), in which nine participants received a subcutaneous inoculation with 0.5 ml of a 1.4 × 103 plaque-forming unit per ml suspension of the attenuated DENV-3 strain CH53489. The primary and secondary endpoints of the study were to assess the safety of this DENV-3 strain in healthy flavivirus-seronegative individuals...
April 1, 2024: Nature Microbiology
https://read.qxmd.com/read/38559801/lupus-nephritis-presenting-with-massive-ascites-and-pleural-effusion-pseudo-pseudo-meigs-syndrome
#24
Rabia Deniz, Gülşah Hacımurtazaoğlu-Demir, Bilgin Karaalioğlu, Duygu Sevinç Özgür, Gamze Akkuzu, Fatih Yıldırım, Cemal Bes
The triad of ascites, pleural effusion, and elevated cancer antigen-125 (CA-125) levels in the absence of ovarian malignancy in systemic lupus erythematosus patients is specifically named pseudo-pseudo Meigs' syndrome (PPMS) or Tjalma syndrome. In this case we reported a 33 years female patient with pleural effusion lasting for 3 years and new onset progressive massive ascites and increased level of CA-125. After she was evaluated for an underlying benign and malign ovarian tumor or any other malignancies, serologic tests were requested with respect to progressive renal dysfunction, proteinuria, lymphopenia, anemia, and effusion...
April 1, 2024: Journal of rheumatic diseases
https://read.qxmd.com/read/38555923/anti-cd30-car-t-cells-as-consolidation-after-autologous-haematopoietic-stem-cell-transplantation-in-patients-with-high-risk-cd30-lymphoma-a-phase-1-study
#25
JOURNAL ARTICLE
Natalie S Grover, George Hucks, Marcie L Riches, Anastasia Ivanova, Dominic T Moore, Thomas C Shea, Mary Beth Seegars, Paul M Armistead, Kimberly A Kasow, Anne W Beaven, Christopher Dittus, James M Coghill, Katarzyna J Jamieson, Benjamin G Vincent, William A Wood, Catherine Cheng, Julia Kaitlin Morrison, John West, Tammy Cavallo, Gianpietro Dotti, Jonathan S Serody, Barbara Savoldo
BACKGROUND: Chimeric antigen receptor (CAR) T cells targeting CD30 are safe and have promising activity when preceded by lymphodepleting chemotherapy. We aimed to determine the safety of anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation (HSCT) in patients with CD30+ lymphoma at high risk of relapse. METHODS: This phase 1 dose-escalation study was performed at two sites in the USA. Patients aged 3 years and older, with classical Hodgkin lymphoma or non-Hodgkin lymphoma with CD30+ disease documented by immunohistochemistry, and a Karnofsky performance score of more than 60% planned for autologous HSCT were eligible if they were considered high risk for relapse as defined by primary refractory disease or relapse within 12 months of initial therapy or extranodal involvement at the start of pre-transplantation salvage therapy...
March 28, 2024: Lancet Haematology
https://read.qxmd.com/read/38554725/afamitresgene-autoleucel-for-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma-spearhead-1-an-international-open-label-phase-2-trial
#26
JOURNAL ARTICLE
Sandra P D'Angelo, Dejka M Araujo, Albiruni R Abdul Razak, Mark Agulnik, Steven Attia, Jean-Yves Blay, Irene Carrasco Garcia, John A Charlson, Edwin Choy, George D Demetri, Mihaela Druta, Edouard Forcade, Kristen N Ganjoo, John Glod, Vicki L Keedy, Axel Le Cesne, David A Liebner, Victor Moreno, Seth M Pollack, Scott M Schuetze, Gary K Schwartz, Sandra J Strauss, William D Tap, Fiona Thistlethwaite, Claudia Maria Valverde Morales, Michael J Wagner, Breelyn A Wilky, Cheryl McAlpine, Laura Hudson, Jean-Marc Navenot, Tianjiao Wang, Jane Bai, Stavros Rafail, Ruoxi Wang, Amy Sun, Lilliam Fernandes, Erin Van Winkle, Erica Elefant, Colin Lunt, Elliot Norry, Dennis Williams, Swethajit Biswas, Brian A Van Tine
BACKGROUND: Afamitresgene autoleucel (afami-cel) showed acceptable safety and promising efficacy in a phase 1 trial (NCT03132922). The aim of this study was to further evaluate the efficacy of afami-cel for the treatment of patients with HLA-A*02 and MAGE-A4-expressing advanced synovial sarcoma or myxoid round cell liposarcoma. METHODS: SPEARHEAD-1 was an open-label, non-randomised, phase 2 trial done across 23 sites in Canada, the USA, and Europe. The trial included three cohorts, of which the main investigational cohort (cohort 1) is reported here...
March 27, 2024: Lancet
https://read.qxmd.com/read/38553357/clinical-characteristics-and-prognosis-of-sars-cov-2-infection-in-children-with-hematological-malignancies-a-multicenter-retrospective-study-in-china
#27
JOURNAL ARTICLE
Weilin Wang, Xueju Xu, Songting Bai, Lu Wang, Jixia Luo, Daiyan Zhao, Ping Li, Qiuxia Fan, Chunmei Wang, Qianghua Yao, Bai Li, Dao Wang
BACKGROUND: Data on SARSCoV-2 infection in children with hematological malignancies (HM) are limited. Here, we describe the clinical features of children with HM after SARS-CoV-2 infection and investigate the potential risk factors for disease severity. METHODS: Children with HM and SARS-CoV-2 infection from five hospitals in five cities in Henan, China from October 2022 to January 2023 were retrospectively included. Clinical information and Coronavirus disease 2019 (COVID-19) vaccination status were collected for further analyses...
March 22, 2024: Pediatrics and Neonatology
https://read.qxmd.com/read/38550590/t-cell-count-and-t-cell-telomere-length-in-patients-with-severe-covid-19
#28
JOURNAL ARTICLE
Bryan D Kraft, Simon Verhulst, Tsung-Po Lai, Bruce A Sullenger, Yunfei Wang, Wes Rountree, Lingye Chen, Christopher W Woods, Thomas N Denny, Abraham Aviv
Lymphocyte telomere length (TL) is highly variable and shortens with age. Short telomeres may impede TL-dependent T-cell clonal expansion with viral infection. As SARS-CoV-2 infection can induce prolonged and severe T-cell lymphopenia, infected adults, and particularly older adults with short telomeres, may display severe T-cell lymphopenia. To examine the relationship between T-cell TL parameters and T-cell counts, we studied 40 patients hospitalized with severe COVID-19. T-cells were isolated from lymphocytes, counted using flow cytometry, and their TL parameters were measured using the Telomere Shortest Length Assay...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38549186/therapeutic-choices-and-disease-activity-after-2%C3%A2-years-of-treatment-with-cladribine-an-italian-multicenter-study-cladstop
#29
JOURNAL ARTICLE
Irene Schiavetti, Alessio Signori, Angela Albanese, Jessica Frau, Eleonora Cocco, Lorena Lorefice, Sonia di Lemme, Roberta Fantozzi, Diego Centonze, Doriana Landi, Girolama Marfia, Elisabetta Signoriello, Giacomo Lus, Chiara Zecca, Claudio Gobbi, Rosa Iodice, Leonardo Malimpensa, Cinzia Cordioli, Diana Ferraro, Francesca Ruscica, Livia Pasquali, Anna Repice, Paolo Immovilli, Maria Teresa Ferrò, Simona Bonavita, Massimiliano Di Filippo, Gianmarco Abbadessa, Flora Govone, Maria Pia Sormani
BACKGROUND AND PURPOSE: Cladribine tablets, a purine analogue antimetabolite, offer a unique treatment regimen, involving short courses at the start of the first and second year, with no further treatment needed in years 3 and 4. However, comprehensive evidence regarding patient outcomes beyond the initial 24 months of cladribine treatment is limited. METHODS: This retrospective, multicenter study enrolled 204 patients with multiple sclerosis who had completed the 2-year course of cladribine treatment...
March 28, 2024: European Journal of Neurology
https://read.qxmd.com/read/38547893/load703-an-oncolytic-virus-based-immunostimulatory-gene-therapy-combined-with-chemotherapy-for-unresectable-or-metastatic-pancreatic-cancer-lokon001-results-from-arm-1-of-a-non-randomised-single-centre-phase-1-2-study
#30
JOURNAL ARTICLE
Benjamin L Musher, Eric K Rowinsky, Brandon G Smaglo, Wasif Abidi, Mohamed Othman, Kalpesh Patel, Salmaan Jawaid, James Jing, Amanda Brisco, Ann M Leen, Mengfen Wu, Linda C Sandin, Jessica Wenthe, Emma Eriksson, Gustav J Ullenhag, Bambi Grilley, Justyna Leja-Jarblad, Susan G Hilsenbeck, Malcolm K Brenner, Angelica S I Loskog
BACKGROUND: Pancreatic ductal adenocarcinoma is characterised by low immunogenicity and an immunosuppressive tumour microenvironment. LOAd703, an oncolytic adenovirus with transgenes encoding TMZ-CD40L and 4-1BBL, lyses cancer cells selectively, activates cytotoxic T cells, and induces tumour regression in preclinical models. The aim of this study was to evaluate the safety and feasibility of combining LOAd703 with chemotherapy for advanced pancreatic ductal adenocarcinoma. METHODS: LOKON001 was a non-randomised, phase 1/2 study conducted at the Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA, and consisted of two arms conducted sequentially; the results of arm 1 are presented here...
April 2024: Lancet Oncology
https://read.qxmd.com/read/38545444/hematological-abnormalities-and-associated-factors-among-patients-with-hypothyroidism-at-the-university-of-gondar-comprehensive-specialized-hospital
#31
JOURNAL ARTICLE
Dereje Mengesha Berta, Yemataw Gelaw, Elias Shiferaw, Abateneh Melkamu, Gebrehiwot Lema Legese, Tiruneh Adane, Befikad Mandefro
OBJECTIVE: Abnormalities in blood cells are frequently associated with thyroid hormone disorders as a result of their involvement in the proliferation and production of blood cells. This study aimed to determine the magnitude and associated factors of hematological abnormalities in patients with hypothyroidism. METHODS: A cross-sectional study was conducted from January 1 to June 30, 2023, at the University of Gondar Comprehensive Specialized Hospital. The present study included a total of 300 patients with hypothyroidism prospectively using the systematic random sampling technique...
2024: Journal of Blood Medicine
https://read.qxmd.com/read/38545096/risk-factors-for-graft-versus-host-disease-after-donor-lymphocyte-infusion-following-t-cell-depleted-allogeneic-stem-cell-transplantation
#32
JOURNAL ARTICLE
Eva A S Koster, Peter A von dem Borne, Peter van Balen, Erik W A Marijt, Jennifer M L Tjon, Tjeerd J F Snijders, Daniëlle van Lammeren, Hendrik Veelken, J H Frederik Falkenburg, Constantijn J M Halkes, Liesbeth C de Wreede
INTRODUCTION: Unmodified donor lymphocyte infusions (DLI) after allogeneic stem cell transplantation (alloSCT) can boost the beneficial Graft-versus-Leukemia (GvL) effect but may also induce severe Graft-versus-Host-Disease (GvHD). To improve the balance between GvL and GvHD, it is crucial to identify factors that influence the alloreactivity of DLI. METHODS: We investigated the effects of the presence of patient-derived antigen-presenting cells at time of DLI as estimated by the bone marrow (BM) chimerism status, lymphopenia as measured by the absolute lymphocyte count (ALC) at time of DLI, and the presence of a viral infection ( de novo or reactivation) close to DLI on the risk of GvHD after DLI...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38543930/long-term-observation-of-sars-cov-2-vaccination-response-upon-high-efficacy-treatment-in-multiple-sclerosis-a-real-world-scenario
#33
JOURNAL ARTICLE
Muriel Schraad, Stefan Runkel, Walter Hitzler, Maria Protopapa, Stefan Bittner, Timo Uphaus, Frauke Zipp
Immunomodulatory and immunosuppressive therapy is needed in people with a chronic neuroinflammatory disease of the central nervous system such as multiple sclerosis (MS). Therefore, MS requires monitoring for and preventing against infectious diseases like SARS-CoV-2. Vaccination and anti-viral treatments are, in particular, recommended for elderly people and people at risk of a severe course of infection and of MS. Here, we asked whether repetitive infection or vaccination influenced responses upon receiving high efficacy treatments, namely sphingosine-1-phosphate receptor modulator (S1P) or anti-CD20 B cell antibody (anti-CD20) treatments...
March 12, 2024: Vaccines
https://read.qxmd.com/read/38538608/regulatory-t-cells-expressing-cd19-targeted-chimeric-antigen-receptor-restore-homeostasis-in-systemic-lupus-erythematosus
#34
JOURNAL ARTICLE
M Doglio, A Ugolini, C Bercher-Brayer, B Camisa, C Toma, R Norata, S Del Rosso, R Greco, F Ciceri, F Sanvito, M Casucci, A A Manfredi, C Bonini
Systemic Lupus Erythematosus (SLE) is a progressive disease leading to immune-mediated tissue damage, associated with an alteration of lymphoid organs. Therapeutic strategies involving regulatory T (Treg) lymphocytes, which physiologically quench autoimmunity and support long-term immune tolerance, are considered, as conventional treatment often fails. We describe here a therapeutic strategy based on Tregs overexpressing FoxP3 and harboring anti-CD19 CAR (Fox19CAR-Tregs). Fox19CAR-Tregs efficiently suppress proliferation and activity of B cells in vitro, which are relevant for SLE pathogenesis...
March 27, 2024: Nature Communications
https://read.qxmd.com/read/38537062/late-cytomegalovirus-disease-after-hematopoietic-cell-transplantation-significance-of-novel-transplantation-techniques
#35
JOURNAL ARTICLE
Alicja Sadowska-Klasa, Sezen Özkök, Hu Xie, Wendy M Leisenring, Danniel Zamora, Sachiko Seo, Jordan Sheldon, Stephanie J Lee, Keith R Jerome, Margaret L Green, Michael J Boeckh
Pre-emptive therapy (PET) and letermovir prophylaxis are effective in preventing CMV disease within the first 100 days after allogeneic hematopoietic cell transplantation (HCT) but are associated with late-onset CMV disease. We retrospectively examined the clinical manifestations, risk factors, prevention algorithm, and outcome of late CMV disease in CMV seropositive day 100 survivors transplanted between 2001-2017 (PET cohort) and 2018-2021 (letermovir cohort). There were 187 episodes of late CMV disease among 2469 day 100 survivors and the estimated cumulative incidence of first late CMV disease was 6...
March 27, 2024: Blood Advances
https://read.qxmd.com/read/38523375/early-neonatal-outcomes-in-infants-of-mothers-with-organ-transplantation-under-immunosuppressive-treatment
#36
JOURNAL ARTICLE
Kıymet Çelik, Sema Arayıcı, Nurten Özkan Zarif, Zeynep Kıhtır, Hakan Ongun, Bülent Aydınlı
BACKGROUND: This study aimed to examine early clinical and laboratory findings in infants born to mothers who had organ transplants and received immunosuppressive treatment. METHODS: Between 2016 and 2023, the study examined infants of mothers who underwent organ transplantation and were receiving immunosuppressive treatment, and followed at the Department of Neonatology at Akdeniz University. Demographic, clinical, and laboratory characteristics of mothers and infants were recorded...
2024: Turkish Journal of Pediatrics
https://read.qxmd.com/read/38521459/lymphopenia-associated-with-survivin-and-its-downstream-pathway-in-covid-19-serving-as-a-potential-route-in-covid-19-pathogenesis
#37
JOURNAL ARTICLE
Mohammad Saeed Kahrizi, Kamyar Nasiri, Farnoosh Ebrahimzadeh, Amirhossein Fakhre Yaseri, Soroush Ghodratizadeh, Mostafa Gholamrezaei, Alireza Rahat Dahmardeh, Ali Adili, Rosita Amjidifar, Maryam Hemmatzadeh, Mohsen Arabi, Mohammad Reza Maghsoudi, Hamed Mohammadi
PURPOSE: Starting in 2019, coronavirus disease 2019 (COVID-19) caused an epidemic that was growing rapidly and has harmed millions of people globally. It has been demonstrated that survivin regulates lymphocyte survival, a main route involved in COVID-19 pathogenesis. Survivin belongs to the inhibitor of apoptosis protein (IAP) family, and its primary functions comprise regulating mitosis and inhibiting apoptosis. Since lower survivin expression has been shown to increase the sensitivity of lymphocytes to apoptotic induction, we looked into the function of survivin and its corresponding pathways in COVID-19 pathogenesis...
March 21, 2024: Advances in Medical Sciences
https://read.qxmd.com/read/38519913/an-international-phase-ii-trial-and-immune-profiling-of-sbrt-and-atezolizumab-in-advanced-pretreated-colorectal-cancer
#38
JOURNAL ARTICLE
Antonin Levy, Daphné Morel, Matthieu Texier, Roger Sun, Jerome Durand-Labrunie, Maria E Rodriguez-Ruiz, Severine Racadot, Stéphane Supiot, Nicolas Magné, Stacy Cyrille, Guillaume Louvel, Christophe Massard, Loic Verlingue, Fanny Bouquet, Alberto Bustillos, Lisa Bouarroudj, Clément Quevrin, Céline Clémenson, Michele Mondini, Lydia Meziani, Lambros Tselikas, Rastilav Bahleda, Antoine Hollebecque, Eric Deutsch
BACKGROUND: Immuno-radiotherapy may improve outcomes for patients with advanced solid tumors, although optimized combination modalities remain unclear. Here, we report the colorectal (CRC) cohort analysis from the SABR-PDL1 trial that evaluated the PD-L1 inhibitor atezolizumab in combination with stereotactic body radiation therapy (SBRT) in advanced cancer patients. METHODS: Eligible patients received atezolizumab 1200 mg every 3 weeks until progression or unmanageable toxicity, together with ablative SBRT delivered concurrently with the 2nd cycle (recommended dose of 45 Gy in 3 fractions, adapted upon normal tissue tolerance constraint)...
March 23, 2024: Molecular Cancer
https://read.qxmd.com/read/38519281/analysis-of-the-reasons-for-requesting-hiv-serology-in-the-emergency-department-other-than-those-defined-in-the-targeted-screening-strategy-of-the-urg%C3%A3-ncies-vihgila-program-and-its-potential-inclusion-in-a-future-consensus-document
#39
JOURNAL ARTICLE
Òscar Miró, Emília Miró, Juan González Del Castillo, Míriam Carbó, Alexis Rebollo, Rocío de Paz, Josep Maria Guardiola, Alejandro Smithson, Daniel Iturriza, Cristina Ramió Lluch, Connie Leey, José Ignacio Ferro, Mireia Saura, Jordi Llaneras, Núria Ros, Neus Robert, Emma Picart Puertas, Margarita Sotomayor, Ferran Rodríguez Masià, Paul Salazar, David Domínguez-Fandos, Silvia Buxo, Cristina Oliazola, Alberto Villamor, Emili Gené
OBJECTIVE: To describe other reasons for requesting HIV serology in emergency departments (ED) other than the 6 defined in the SEMES-GESIDA consensus document (DC-SEMES-GESIDA) and to analyze whether it would be efficient to include any of them in the future. METHODS: Review of all HIV serologies performed during 2 years in 20 Catalan EDs. Serologies requested for reasons not defined by the DC-SEMES-GESIDA were grouped by common conditions, the prevalence (IC95%) of seropositivity for each condition was calculated, and those whose 95% confidence lower limit was >0...
March 21, 2024: Enfermedades infecciosas y microbiologia clinica
https://read.qxmd.com/read/38519028/role-of-teplizumab-a-humanized-anti-cd3-monoclonal-antibody-in-managing-newly-diagnosed-type-1-diabetes-an-updated-systematic-review-and-meta-analysis
#40
JOURNAL ARTICLE
A B M Kamrul-Hasan, Sunetra Mondal, Lakshmi Nagendra, Ashmita Yadav, Fatema Tuz Zahura Aalpona, Deep Dutta
BACKGROUND: Teplizumab has emerged as a potential disease-modifying drug in type 1 diabetes (T1D). This meta-analysis sought to summarize the therapeutic effect of teplizumab in newly diagnosed patients with T1D. METHODS: Randomized controlled trials (RCTs) involving patients with T1D receiving teplizumab in the intervention arm and placebo (or no active intervention) in the control arm were searched throughout the electronic databases. The primary outcome was the change in area under the curve (AUC) of C-peptide levels from baseline...
March 20, 2024: Endocrine Practice
keyword
keyword
86089
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.